Molecular Partners Notifies Availability of Press Release
PUBT · 1d ago
Share
Listen to the news
- Molecular Partners posted a July 15, 2026 update on its bispecific Radio-DARPin radioligand therapy strategy, presented at the Gordon Research Conference.
- Highlight centered on multispecific Radio-DARPins designed to address tumor heterogeneity by engaging multiple targets to improve precision.
- Lead DLL3 program MP0712 remains in a US Phase 1/2a trial; mesothelin-targeting MP0726 is working toward first human imaging this year.
- Presentation copy to be posted on the company website under Scientific Documents.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Molecular Partners AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607150100PRIMZONEFULLFEED9762212) on July 15, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved